IL33 and melanoma: Schuijs et al. found that intranasally administration of low-dose IL-33 could activate group 2 innate lymphoid cells (ILC2s) which orchestrated suppression of NK cell-mediated innate anti-tumor immunity, leading to increased melanoma lung metastases [15].